Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Capital Expenditures (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Capital Expenditures for 3 consecutive years, with -$134000.0 as the latest value for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 309.38% year-over-year to -$134000.0; the TTM value through Dec 2025 reached $292000.0, down 54.52%, while the annual FY2025 figure was $292000.0, 54.52% down from the prior year.
  • Capital Expenditures hit -$134000.0 in Q4 2025 for Artiva Biotherapeutics, down from $143000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $882000.0 in Q1 2025 and bottomed at -$599000.0 in Q2 2025.
  • Average Capital Expenditures over 3 years is $174900.0, with a median of $103500.0 recorded in 2024.
  • On a YoY basis, Capital Expenditures climbed as much as 6684.62% in 2025 and fell as far as 3095.0% in 2025.
  • Artiva Biotherapeutics' Capital Expenditures stood at $636000.0 in 2023, then plummeted by 89.94% to $64000.0 in 2024, then tumbled by 309.38% to -$134000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$134000.0, $143000.0, and -$599000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.